ScholarIQanswers from OpenAlex & ORCID
Sven G. Meuth
ResearcherPublications, citations & collaboration network
Sven G. Meuth is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Sven G. Meuth have?
ScholarIQindexed works
Sven G. Meuth has 955 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Sven G. Meuth have?
ScholarIQcitation count
Sven G. Meuth has 26,469 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Sven G. Meuth?
ScholarIQh-index
Sven G. Meuth has an h-index of 84 in OpenAlex.
What is the i10-index of Sven G. Meuth?
ScholarIQi10-index
Sven G. Meuth has an i10-index of 490 in OpenAlex.
What is the ORCID of Sven G. Meuth?
ScholarIQorcid
The ORCID for Sven G. Meuth is on the source record.
What is the OpenAlex record for Sven G. Meuth?
ScholarIQopenalex
The OpenAlex for Sven G. Meuth is on the source record.
What are the most-cited papers on Sven G. Meuth?
ScholarIQmost cited works
Post-Stroke Inhibition of Induced NADPH Oxidase Type 4 Prevents Oxidative Stress and Neurodegeneration
Christoph Kleinschnitz, Henrike Grund, Kirstin Wingler, M.E. Armitage, Emma S. Jones, Manish Mittal, David Barit, Tobias Schwarz, Christian Geis, Peter Kraft, K Barthel, Michael K. Schuhmann, Alexander M. Herrmann, Sven G. Meuth, Guido Stoll, Sabine Meurer, Anja Schrewe, Lore Becker, Valérie Gailus-Durner, Helmut Fuchs, Thomas Klopstock, Martin Hrabě de Angelis, Karin Jandeleit‐Dahm, Ajay M. Shah, Norbert Weißmann, Harald Schmidt
Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension
Raju Kapoor, Pei‐Ran Ho, Nolan Campbell, Ih Chang, Aaron Deykin, Fiona Forrestal, Nisha Lucas, Bei Yu, Douglas L. Arnold, Mark S. Freedman, Myla Goldman, Hans-Peter Hartung, Eva Havrdová, Douglas Jeffery, A Miller, Finn Sellebjerg, Diego Cadavid, Dan Mikol, Deborah Steiner, E Bartholomé, Marie D’hooghe, Massimo Pandolfo, Bart Van Wijmeersch, Virender Bhan, Gregg Blevins, Donald Brunet, Virginia Devonshire, Pierre Duquette, Mark S. Freedman, François Grand’Maison, François Jacques, Yves Lapierre, Liesly Lee, Sarah A. Morrow, Michael Yeung, Michal Dufek, Eva Havrdová, Petr Kaňovský, Ivana Štětkářová, Marika Talábová, Jette Lautrup Frederiksen, Matthias Kant, Thor Petersen, Mads Ravnborg, Finn Sellebjerg, Laura Airas, Irina Elovaara, Juha-Pekka Erälinna, Taneli Sarasoja, Abdullatif Al Khedr, David Brassat, Bruno Brochet, William Camu, Marc Debouverie, David Laplaud, Christine Lebrun‐Frénay, Jean Pelletier, Patrick Vermersch, Sandra Vukusi, Karl Baum, Achim Berthele, Juergen Faiss, Peter Flachenecker, Reinhard Hohlfeld, Markus Krumbholz, Christoph Lassek, Mathias Maeurer, Sven G. Meuth, Tjalf Ziemssen, Orla Hardiman, Christopher McGuigan, Anat Achiron, Dimitrios Karussis, Roberto Bergamaschi, Vincenzo Brescia Morra, Giancarlo Comi, Salvatore Cottone, Luigi M.E. Grimaldi, Giovanni Luigi Mancardi, Luca Massacesi, Ugo Nocentini, Marco Salvetti, Elio Scarpini, Patrizia Sola, Gioacchino Tedeschi, María Trojano, Mauro Zaffaroni, Stephan Frequin, Raymond Hupperts, Joep Killestein, Hans M. Schrijver, Ronald Van Dijl, Erik van Munster, Maciej Czarnecki, Wiesław Drozdowski, Waldemar Fryze, Hanka Hertmanowska, Jan Ilkowski, Anna Kamińska, Gabriela Kłodowska-Duda
Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) – revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management
Tania Kümpfel, Katrin Giglhuber, Orhan Aktaş, Ilya Ayzenberg, Judith Bellmann–Strobl, Vivien Häußler, Joachim Havla, Kerstin Hellwig, Martin W. Hümmert, Sven Jarius, Ingo Kleiter, Luisa Klotz, Markus Krumbholz, Friedemann Paul, Marius Ringelstein, Klemens Ruprecht, Makbule Şenel, Jan‐Patrick Stellmann, Florian Then Bergh, Corinna Trebst, Hayrettin Tumani, Clemens Warnke, Brigitte Wildemann, Achim Berthele, The Neuromyelitis Optica Study Group (NEMOS), Philipp Albrecht, Klemens Angstwurm, Susanna Asseyer, Ana Beatriz Ayroza Galvão Ribeiro Gomes, Antonios Bayas, Stefanie Behnke, Stefan Bittner, Franziska Buetow, Mathias Buttmann, Ankelien Duchow, Daniel Engels, Thorleif Etgen, Katinka Fischer, Benedikt Frank, Anna Gahlen, Achim Gass, Johannes Gehring, Christian Geis, Ralf Gold, Yasemin Göreci, Jonas Graf, Sergiu Groppa, Matthias Grothe, Julia Gutbrod, Kersten Guthke, Axel Haarmann, Maria Hastermann, Bernhard Hemmer, Mariella Herfurth, Marina Herwerth, Frank Hoffmann, Olaf Hoffmann, Martin W. Hümmert, Leila Husseini, Jutta Junghans, Matthias Kaste, Peter Kern, Karsten Kern, Pawel Kermer, Christoph Kleinschnitz, Wolfgang Köhler, Kimberly Körbel, Markus C. Kowarik, Markus Kraemer, Julian Reza Kretschmer, Natalia Kurka, Theodoros Ladopoulus, Ann-Sophie Lauenstein, Sarah Laurent, De-Hyung Lee, Dominik Lehrieder, Frank Leypoldt, Martin Liebetrau, Ralf A. Linker, Gero Lindenblatt, Lisa Lohmann, Felix Lüssi, Peter Luedemann, Michelle Maiworm, Martin Marziniak, Christoph Mayer, Stefanie Meister, Mathias Mering, Imke Metz, Sven G. Meuth, Jasmin Naumann, Oliver Neuhaus, Tradite Neziraj, Moritz Niederschweiberer, Sabine Niehaus, Carolin Otto, Florence Pache, Thivya Pakeerathan, Sarah Passoke, Marc Pawlitzki
Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper)
Heinz Wiendl, Ralf Gold, Thomas Berger, Tobias Derfuß, Ralf A. Linker, Mathias Mäurer, Orhan Aktaş, Karl Baum, Martin Berghoff, Stefan Bittner, Andrew Chan, Adam Czapliński, Florian Deisenhammer, Franziska Di Pauli, Renaud Du Pasquier, Christian Enzinger, Elisabeth Fertl, Achim Gass, Klaus Gehring, Claudio Gobbi, Norbert Goebels, Michael Guger, Aiden Haghikia, Hans‐Peter Hartung, Fedor Heidenreich, Olaf Hoffmann, Boris Kallmann, Christoph Kleinschnitz, Luisa Klotz, Verena I. Leussink, Fritz Leutmezer, Volker Limmroth, Jan D. Lünemann, Andreas Lutterotti, Sven G. Meuth, Uta Meyding‐Lamadé, Michael Platten, Peter Rieckmann, Stephan Schmidt, Hayrettin Tumani, Frank Weber, Martin S. Weber, Uwe K. Zettl, Tjalf Ziemssen, Frauke Zipp, for the ‘Multiple Sclerosis Therapy Consensus Group’ (MSTCG)